Sadri-Azarbayejani, Flora

Sadri-Azarbayejani, Flora was paid $499K by Medicaid between Jan 2018 and Mar 2020, across 11 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 52% of everything it billed.

33Billing provider infoSADRI-AZARBAYEJANI, FLORA
LOWELL, MA 01852

33aNPI1023088820assigned 01/24/2006

33bProvider typeGeneral Practice Physician

28Total paid$499K

24GClaims9,565

24DCodes billed11

24AFirst – last monthJan 2018 – Mar 2020

Compared with peers

Next to other General Practice Physician providers in Massachusetts

Rank by total paid#9 of 33

Median peer was paid$76K

This provider vs. median6.6×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	3,676	$194K
2019	5,630	$295K
2020	259	$10K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	52%	3,733	1,987	$261K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	30%	3,315	1,710	$148K
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	9.2%	862	574	$46K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	7.5%	597	518	$37K
81025		<1%	491	457	$3K
99212	Office or other outpatient visit for the evaluation and management of an established patient, straightforward	<1%	43	40	$1K
80076		<1%	151	149	$1K
86803		<1%	44	44	$467.61
87340		<1%	46	46	$437.06
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	16	16	$371.04
H0003	Alcohol and/or drug screening; laboratory analysis of specimens for presence of alcohol and/or drugs	<1%	267	192	$2.67

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.